Baker Hughes, Repsol to Develop Next Generation Digital Capabilities Through Leucipa(TM)

Companies will develop new AI-powered processes and workflows to achieve further optimization in oil and gas production Knowledge sharing will enhance Leucipa’s capabilities HOUSTON and LONDON, Oct. 14, 2024 (GLOBE NEWSWIRE) — Baker Hughes (NASDAQ: BKR), an energy technology company, and Repsol, a global multi-energy company, announced Monday a new agreement to collaboratively develop and […]

Descartes Acquires Sellercloud

Adds Inventory Management and Order Management Capabilities to Descartes’ Ecommerce Suite WATERLOO, Ontario and ATLANTA, Oct. 14, 2024 (GLOBE NEWSWIRE) — Descartes Systems Group (TSX:DSG) (Nasdaq:DSGX), the global leader in uniting logistics-intensive businesses in commerce, announced that it has acquired Sellercloud, a leading provider of omnichannel ecommerce solutions. Based in the US, Sellercloud supports small

BioCryst to Present New Real-World Evidence Showing Significant Reductions in Medical Visits and Hospitalizations After Starting ORLADEYO(R) (berotralstat)

RESEARCH TRIANGLE PARK, N.C., Oct. 14, 2024 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO(R) (berotralstat) demonstrating that patients with hereditary angioedema (HAE) in the United States experience significant reductions in healthcare resource utilization (HRU), including significant reductions in hospitalizations, emergency room visits

OTC Markets Group Welcomes Blumetric Environmental, Inc. to OTCQX

NEW YORK, Oct. 14, 2024 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Blumetric Environmental, Inc. (TSX-V: BLM; OTCQX: BLMWF), (“BluMetric”) an integrated product and service organization, has qualified to trade on the OTCQX(R) Best Market. BluMetric Environmental, Inc. upgraded to

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Poster presentation to highlight data from completed first-in-human, Phase 1 ascending dose clinical trial of ADX-097 in healthy volunteers; results support Phase 2 dose selection and continued clinical advancement of ADX-097 — Q32 Bio Inc. (Nasdaq: QTTB) (“Q32 Bio”), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced

Auddia Announces Higher Than Expected Success in User Retention and Shifts Focus to Optimizing Subscription Conversions

faidr 30-day retention has grown from 5% to 12% in the last year, 2% above Auddia’s targeted 30-day retention goal Company now shifts focus down funnel to optimize subscription conversion metrics to drive high margin revenue BOULDER, Colo., Oct. 14, 2024 (GLOBE NEWSWIRE) — Auddia Inc. (NASDAQ:AUUD) (NASDAQ:AUUDW) (“Auddia” or the “Company”), a proprietary AI

KOALA AI Celebrates Major Exchange Listings and Key Milestones in Project Growth

London, UK , Oct. 14, 2024 (GLOBE NEWSWIRE) — KOALA AI ($KOKO) is proud to announce significant progress in its journey, including listings on major exchanges such as Gate.io, Bitget, MEXC, and BingX. These new listings mark a pivotal moment in KOALA AI’s growth, increasing accessibility and liquidity for its fast-expanding community of over 18,000

Timken to Announce Third-Quarter 2024 Financial Results on Nov. 5

The Timken Company (NYSE: TKR; www.timken.com), a global technology leader in engineered bearings and industrial motion, will release its third-quarter 2024 financial results on Tuesday, Nov. 5, prior to the opening of the New York Stock Exchange.The company will host a conference call that day to discuss its financial performance with investors and securities analysts.

Ferrari N.V.: Periodic Report on the Buyback Program

Maranello (Italy), October 14, 2024 – Ferrari N.V. (NYSE/EXM: RACE) (“Ferrari” or the “Company“) informs that the Company has purchased, under the Euro 250 million share buyback program announced on June 28, 2024, as the fifth tranche of the multi-year share buyback program of approximately Euro 2 billion expected to be executed by 2026 in

BD Announces New Robotics Solution to Automate, Standardize Single-Cell Research

Automation-Ready Reagents Used with the Hamilton Robotics Liquid-Handler Streamlines and Helps Accelerate Lab Work Leading to Genomic Sequencing BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial launch of the first in a family of high-throughput, robotics-compatible reagent kits that will enable automation to ensure greater consistency

Scroll to Top